| pubmed-article:9519890 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9519890 | lifeskim:mentions | umls-concept:C0030899 | lld:lifeskim |
| pubmed-article:9519890 | lifeskim:mentions | umls-concept:C1456820 | lld:lifeskim |
| pubmed-article:9519890 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:9519890 | lifeskim:mentions | umls-concept:C0238607 | lld:lifeskim |
| pubmed-article:9519890 | lifeskim:mentions | umls-concept:C0348016 | lld:lifeskim |
| pubmed-article:9519890 | lifeskim:mentions | umls-concept:C0033268 | lld:lifeskim |
| pubmed-article:9519890 | lifeskim:mentions | umls-concept:C0205289 | lld:lifeskim |
| pubmed-article:9519890 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:9519890 | pubmed:dateCreated | 1998-5-1 | lld:pubmed |
| pubmed-article:9519890 | pubmed:abstractText | Tumor necrosis factor alpha (TNF-alpha) may be involved in the pathogenesis of metabolic and endocrine changes in HIV infection. Pentoxifylline (PTX) is able to suppress the production of TNF-alpha in vitro. The effect of two dosages of intravenously administered PTX on clinical symptoms and ex vivo LPS-stimulated TNF-alpha production was evaluated in six clinically stable AIDS patients in a saline-controlled study. PTX in a dosage of 1.5 mg/min was tolerated without side effects. PTX in a dosage of 2.1 mg/min resulted in intolerable nausea and necessitated termination of infusion after 30 min. The average plasma concentration of PTX after infusion of 1.5 mg/min for 6 hr was 510+/-56 ng/ml, which is considerably below the concentrations that have been reported to suppress TNF-alpha production in vitro. No effect of PTX infusion (1.5 mg/min) on LPS-stimulated TNF production ex vivo was found. Our conclusion is that the maximally tolerated i.v. dosage of PTX in AIDS patients is 1.5 mg/min. LPS-stimulated ex vivo TNF-alpha production, at the LPS concentrations tested, was not inhibited by the plasma concentration of PTX that could be achieved at this dosage. | lld:pubmed |
| pubmed-article:9519890 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9519890 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9519890 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9519890 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9519890 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9519890 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9519890 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9519890 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9519890 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:9519890 | pubmed:issn | 0889-2229 | lld:pubmed |
| pubmed-article:9519890 | pubmed:author | pubmed-author:EndersBB | lld:pubmed |
| pubmed-article:9519890 | pubmed:author | pubmed-author:SauerweinH... | lld:pubmed |
| pubmed-article:9519890 | pubmed:author | pubmed-author:AckermannHH | lld:pubmed |
| pubmed-article:9519890 | pubmed:author | pubmed-author:TimmerJ GJG | lld:pubmed |
| pubmed-article:9519890 | pubmed:author | pubmed-author:RomijnJ AJA | lld:pubmed |
| pubmed-article:9519890 | pubmed:author | pubmed-author:Heijligenberg... | lld:pubmed |
| pubmed-article:9519890 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9519890 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:9519890 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:9519890 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9519890 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9519890 | pubmed:pagination | 299-303 | lld:pubmed |
| pubmed-article:9519890 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9519890 | pubmed:meshHeading | pubmed-meshheading:9519890-... | lld:pubmed |
| pubmed-article:9519890 | pubmed:meshHeading | pubmed-meshheading:9519890-... | lld:pubmed |
| pubmed-article:9519890 | pubmed:meshHeading | pubmed-meshheading:9519890-... | lld:pubmed |
| pubmed-article:9519890 | pubmed:meshHeading | pubmed-meshheading:9519890-... | lld:pubmed |
| pubmed-article:9519890 | pubmed:meshHeading | pubmed-meshheading:9519890-... | lld:pubmed |
| pubmed-article:9519890 | pubmed:meshHeading | pubmed-meshheading:9519890-... | lld:pubmed |
| pubmed-article:9519890 | pubmed:meshHeading | pubmed-meshheading:9519890-... | lld:pubmed |
| pubmed-article:9519890 | pubmed:meshHeading | pubmed-meshheading:9519890-... | lld:pubmed |
| pubmed-article:9519890 | pubmed:meshHeading | pubmed-meshheading:9519890-... | lld:pubmed |
| pubmed-article:9519890 | pubmed:meshHeading | pubmed-meshheading:9519890-... | lld:pubmed |
| pubmed-article:9519890 | pubmed:meshHeading | pubmed-meshheading:9519890-... | lld:pubmed |
| pubmed-article:9519890 | pubmed:meshHeading | pubmed-meshheading:9519890-... | lld:pubmed |
| pubmed-article:9519890 | pubmed:meshHeading | pubmed-meshheading:9519890-... | lld:pubmed |
| pubmed-article:9519890 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9519890 | pubmed:articleTitle | The maximal tolerable intravenous dosage of pentoxifylline in AIDS patients does not inhibit lipopolysaccharide-stimulated tumor necrosis factor alpha production. | lld:pubmed |
| pubmed-article:9519890 | pubmed:affiliation | Department of Endocrinology and Metabolism, Academic Hospital of Amsterdam University, The Netherlands. | lld:pubmed |
| pubmed-article:9519890 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9519890 | pubmed:publicationType | In Vitro | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9519890 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9519890 | lld:pubmed |
